Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office, a Philadelphia plaintiff firm, is soliciting current shareholders of Aardvark Therapeutics (NASDAQ: AARD), Erasca (NASDAQ: ERAS), Hub Group (NASDAQ: HUBG), and New Era Energy & Digital (NASDAQ: NUAI) to pursue claims and shareholder governance actions at no cost. For Aardvark, the release recaps a securities class action alleging the February 2025 IPO documents overstated the safety of lead drug ARD-101, citing the February 2026 Phase 3 HERO enrollment pause and the May 2026 FDA full clinical hold, after which the stock allegedly fell approximately 56% and then another 32.1%.
Key figures
- Drug Name
- ARD-101
- Phase Of Trial
- Phase 3
- Ard ipo date
- February 13, 2025
- Nuai ipo date
- December 9, 2024
- Nm ag lawsuit date
- December 29, 2025
- Ard stock decline 1
- -56% (alleged decline after Feb 27, 2026 HERO enrollment pause)
- Ard stock decline 2
- -32.1% (alleged decline after May 14, 2026 FDA clinical hold)
- Ard close 2026 03 02
- 5.47
- Eras disclosure date
- April 27, 2026
- Erd full clinical hold date
- May 14, 2026
- Ard close after clinical hold
- 4.57
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.